

For Immediate Release

Net Profit up 281 %, Net Revenues up 81%

Vadodara, 21st January, 2016

Alembic Pharmaceuticals Limited reported its performance for the Third quarter ending 31st December 2015.

Financial Highlights

- Net Sales up 81% to Rs 931 Crore
- Net Profit up 281% to Rs 269 Crore
- India Branded up by 15% to Rs 288 Crore
- International Business up 248% to Rs 521 Crore
- API Business up 24% to Rs 101 Crore

Commenting on the results, Mr. Shaunak Amin, Joint Managing Director, Alembic Pharmaceuticals Limited said “We have seen exceptional growth in all our businesses. The US business continues to outperform on the back of the Aripiprazole Generic launch. Our facilities have been in compliance and we have received 11 ANDA approvals this year.”

Operational Highlights

India Branded Formulations

- Sikkim plant commissioned
- India Branded formulations business grew 15% to Rs 288 Crore
- Specialty Segment grew 22%
 - Cardiology up 34%
 - Anti Diabetic up 43%
 - Gynaecology up 29%
- Alembic’s “Tellzy” is the fastest growing Telmisartan brand

International Formulations

- International Formulations business grew 248% to Rs 521 crore in the quarter
- 2 ANDA approvals received in the quarter
- 3 ANDA applications filed, Cumulative ANDA filings at 74
- 4 DMF applications filed, Cumulative DMF filings at 79

Summary of Total Revenue is as under:

(Rs in Lacs)						
Particulars	Q3 FY16	Q3 FY15	% Change	YTD DEC FY16	YTD DEC FY15	% Change
Formulation						
International	52110	14986	248%	127132	43513	192%
India Branded	28827	24997	15%	83562	74876	12%
India Generics	2005	3321	-40%	7374	9065	-19%
API	10124	8186	24%	35803	28524	26%
Total	93066	51490	81%	253871	155978	63%

The Profit break-up is as under:

(Rs in Lacs)						
Particulars	Q3 FY16	Q3 FY15	% Change	YTD DEC FY16	YTD DEC FY15	% Change
EBITDA	38460	10157	279%	86268	30502	183%
Profit Before Tax	36471	8998	305%	81538	27060	201%
Net Profit after Tax	26949	7066	281%	62826	21260	196%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai Phone: +91 22 – 306 11681 Email: ajay.desai@alembic.co.in	Mitanshu Shah Phone: +91 265 – 3007630 Email: mitanshu.shah@alembic.co.in
---	---